However, after those 6 years, CHEK2 c.1100delC was associated with a worse distant disease-free survival (HR = 2.7; 95 %CI = 1.8–3.9) and breast cancer-specific survival (HR = 2.1; 95 %CI = 1.4–3.0) [3]. Here, CHEK2 is linked to breast cancer.